Formulations of phosphoramidate derivatives of nucleoside drugs
AssigneeNuCana plc
InventorsGordon Kennovin, Hugh Griffith
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations which comprise a polar aprotic solvent, for example dimethyl acetamide (DMA).
Claims31
A pharmaceutical formulation for infusion to a human patient in need thereof comprising:
- 5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L alaninyl)] phosphate (NUC-3373) or a pharmaceutically acceptable salt thereof;
- dimethyl acetamide (DMA);
- an aqueous vehicle;
- and
- optionally one or more pharmaceutically acceptable excipients.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating cancer, the method comprising infusing to a human patient in need thereof a pharmaceutical formulation comprising:
- NUC-3373;
- DMA;
- and
- optionally one or more pharmaceutically acceptable excipients.
(canceled)
(canceled)
(canceled)
(canceled)
A kit comprising:
- a first formulation comprising DMA, NUC-3373 and optionally an aqueous vehicle;
- and
- a second formulation comprising DMA and one or more solubilizers.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.